Candel Therapeutics (NASDAQ:CADL – Get Free Report) and Gossamer Bio (NASDAQ:GOSS – Get Free Report) are both small-cap healthcare companies, but which is the superior business? Get Candel Therapeutics alerts:Institutional and Insider Ownership13.9% of Candel Therapeutics shares are held by institutional investors. Analyst RatingsSell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Candel Therapeutics 1 2 7 0 2.60 Gossamer Bio 2 3 4 0 2.22This is a breakdown of current recommendations for Candel Therapeutics and Gossamer Bio, as reported by MarketBeat.com. Given Gossamer Bio’s higher probable upside, analysts clearly believe Gossamer Bio is more favorable than Candel Therapeutics. Net Margins Return on Equity Return on Assets Candel Therapeutics N/A -60.42% -41.33% Gossamer Bio -324.82% N/A -96.10%SummaryGossamer Bio beats Candel Therapeutics on 7 of the 13 factors compared between the two stocks.